Medical professionals will soon have access to a new device to treat the 3.24 million Australians who suffer chronic pain and it’s already been given TGA-approval.

US based Nevro’s Omnia Spinal Cord Stimulation System delivers treatment for chronic back pain using frequency technology to stimulate the spinal cord. 

It is the only product of its kind that can deliver all frequencies, between two and 10,000HZ. It also offers a waveform pioneered by Omnia, the HF10, which was found to reduce pain across two 24-month trials. In the SENZA-EU study, a multicenter back pain study conducted in Europe, the average opioid intake of the patients was decreased by nearly 70%, and the percentage of patients not taking opioids by two years had tripled (from 14% to 42%).

Nevro’s Chief Commercial Officer Niamh Pellegrini said the product will be available to medical practitioners across Australia from July 1, following successful launches in the United States and Europe.

“Omnia was developed as a result of extensive feedback from physicians to provide a versatile solution to help more patients with chronic pain,” Ms Pellegrini said. 

“With Omnia, patients will have access to the widest range of SCS frequencies, and physicians can have the peace of mind knowing they can provide their patients the broadest range of solutions for the best possible outcomes.”

The system is made up of a number of new components including a programmer which allows medical practitioners to vary the frequencies required by their patients and a remote which makes it easier for patients to use the device. It also features an implantable pulse generator which lasts more than a decade, is MRI safe and can be upgraded for future waveforms and frequencies. 

Pain Specialists Australia Director Nick Christelis said he is looking forward to using Omnia’s updated programming suite.